Scribd Logo
Upload

Welcome to Scribd!

  • EBM - Fish Oil

    Uploaded by

    Marianne R. Lorenzo
    10 views2 pages
    This document summarizes a clinical case involving a 56-year-old male with a history of NSTEMI in July 2020 who is maintained on Clopidogrel and Atorvastatin. His current labs show a triglyceride level of 200 mg/dl and LDL of 80 mg/dl. Research was conducted on whether omega-3 fatty acid supplementation is effective in reducing cardiovascular events among patients with high triglycerides. The conclusion is that icosapent ethyl reduces ischemic events in patients with elevated triglycerides compared to placebo, and it will be recommended for this patient.

    Original Description:

    Original Title

    EBM_Fish Oil

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document summarizes a clinical case involving a 56-year-old male with a history of NSTEMI in July 2020 who is maintained on Clopidogrel and Atorvastatin. His current labs show a triglyceride level of 200 mg/dl and LDL of 80 mg/dl. Research was conducted on whether omega-3 fatty acid supplementation is effective in reducing cardiovascular events among patients with high triglycerides. The conclusion is that icosapent ethyl reduces ischemic events in patients with elevated triglycerides compared to placebo, and it will be recommended for this patient.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    10 views2 pages

    EBM - Fish Oil

    Uploaded by

    Marianne R. Lorenzo
    This document summarizes a clinical case involving a 56-year-old male with a history of NSTEMI in July 2020 who is maintained on Clopidogrel and Atorvastatin. His current labs show a triglyceride level of 200 mg/dl and LDL of 80 mg/dl. Research was conducted on whether omega-3 fatty acid supplementation is effective in reducing cardiovascular events among patients with high triglycerides. The conclusion is that icosapent ethyl reduces ischemic events in patients with elevated triglycerides compared to placebo, and it will be recommended for this patient.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    Clinical Scenario

    56/M
    PMHx: NSTEMI July 2020,
    maintained on Clopidogrel and
    Atorvastatin
    Labs: Triglyceride: 200mg/dl; LDL:
    80 mg/dl

    Research Question
    Among patients with high
    triglycerides, does omega 3-fatty
    acid supplementation effective in
    reducing cardiovascular events?
    Clinical Bottomline:
    • Icosapent ethyl is effective
    in reducing ischemic events
    in patient with elevated
    triglycerides when
    compared to placebo.
    • Will recommend to the
    patient.

    You might also like